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Abstract 
Isolated ventricular cardiomyocytes from adult rat have been used to elucidate apossible relationship between protein kinase C (PKC) 
and the stimulatory action of insulin on cardiac glucose transport. Cells were incubated in the presence of either insulin or phospholipase 
C from Clostridium perfringens (PLC-Cp) and intracellular sn-l,2-diacylglycerol (DAG) levels and initial rates of 3-O-methylglucose 
transport were determined. Insulin had no effect on the DAG mass level, whereas it was elevated by PLC-Cp to 200% of control. Under 
these conditions the hormone produced a 2.7-fold stimulation of glucose transport with no significant effect of PLC-Cp. Insulin was 
unable to produce a redistribution of PKC, whereas phorbol 12-myristate 13-acetate (PMA) increased membrane associated PKC twofold. 
The PKC inhibitors tamoxifen and staurosporine did not interfere with glucose transport stimulation by insulin. Furthermore, cells treated 
with PMA exhibited unaltered basal and maximally insulin stimulated rates of glucose transport. In contrast, at physiological 
concentrations of insulin the stimulatory action of the hormone was significantly reduced. We conclude from our data that PKC is not 
involved in insulin action on cardiac glucose transport. However, activation of this enzyme may lead to a modified insulin sensitivity of 
the cardiac cell. 
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1. Introduction 
A primary and essential step of insulin action consists 
in the autoactivation f an intrinsic tyrosine kinase activity 
located in the beta-subunit of the insulin receptor (for 
review, see [1]). Subsequent steps of insulin signalling 
remain obscure and a variety of cellular signal transduction 
elements like G-proteins [2], tyrosine phosphorylated pro- 
teins [3], glycolipids [4], and serine/threonine kinases [5] 
are assumed to modulate or mediate the ultimate action of 
the hormone. 
A serine/threonine kinase which has gained consider- 
able interest as a putative mediator of insulin action is the 
Ca 2+- and phospholipid-dependent protein kinase C (PKC) 
[6-11]. Evidence supporting; this view is based on the 
Abbreviations: PDD, 4-alpha-phorbol 12,13-didecanoate; DAG, sn- 
1,2-diacylglycerol, PKC, protein kinase C; PMA, phorboi 12-myristate 
13-acetate; PLC-Cp, phospholipase C from Clostridium perfringens. 
* Corresponding author. Fax: +4!9 211 3382603. 
0167-4889/95/$09.50 © 1995 Elsevier Science B,V. All rights reserved 
SSD1 0167-4889(94)00200-2  
observation that (i) insulin stimulates an increase in DAG 
[6-8] and a translocation of PKC [8,9] in muscle and 
adipose tissue, (ii) phorbol esters, which are known activa- 
tors of PKC, induce translocation of Glut4 [10] and at least 
partly mimick insulin action on hexose transport [8,11], 
and (iii) down-regulation of PKC blocks stimulation of 
glucose uptake by insulin [11]. In addition to possibly 
mediating insulin action, PKC has also been implicated in 
termination of the insulin signal, a process, which is 
thought o result from serine phosphorylation f the insulin 
receptor fl-subunit and a concomitant decrease of tyrosine 
kinase activity [12,13]. 
Despite the above mentioned studies, the precise func- 
tion of PKC in insulin signal transduction remains an 
unresolved issue. Work performed on different rodent 
skeletal muscle preparations and a variety of cell lines 
indeed argues against a role for PKC in insulin signalling 
[14-18]. Thus, DAG remained unaffected by in vitro [14] 
and in vivo [15] insulin treatment, insulin was unable to 
induce PKC translocation [16] or phosphorylation of a 
cellular substrate protein [17], and PMA had only minimal 
effects on glucose transport [16,18]. 
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In light of these controversial findings we have now 
used our preparation of ventricular cardiomyocytes [19,20] 
in order to reevaluate the functional role of PKC for the 
regulation of glucose transport in a primary muscle cell. 
These cells express a high level of Glut4, which is translo- 
cated to the plasma membrane in response to insulin and 
contraction, as recently shown by us [21]. In addition to 
being a putative mediator of insulin action, PKC has also 
been implicated in the regulation of cardiac contractility 
[22] and in the transduction of mechanical stimuli to a 
hypertrophic response [23]. In the present investigation 
attempts have been made to correlate the level of DAG 
with glucose transport activity and to compare the stimula- 
tory action of insulin and PMA on PKC activity and 
hexose transport in isolated cardiac cells. The data clearly 
show that elevation of DAG mass and activation of PKC 
are events unrelated to the stimulation of glucose transport 
by insulin. It is suggested, however, that PKC is able to 
modulate the sensitivity of cardiomyocytes towards timu- 
lation by insulin. 
2. Materials and methods 
2.1. Isolation of  ventricular cardiomyocytes 
Male Wistar rats weighing 280-320 g were used in all 
experiments. Ca2+-tolerant ventricular myocytes were iso- 
lated by perfusion of the heart with collagenase as previ- 
ously described by us [19]. The final cell suspension was 
washed three times with Hepes buffer (composition: NaC1 
130 raM, KC1 4.8 mM, KH2PO 4 1.2 mM, Hepes 25 mM, 
glucose 5 mM, bovine serum albumin 20 g/1 (pH 7.4), 
equilibrated with oxygen) and incubated in silicone-treated 
Eflenmeyer flasks in a rotating waterbath shaker at 37°C. 
After 20 min CaC12 and MgSO 4 (final concentration 1 
mM) were added and incubation was continued until fur- 
ther use. Cell viability was checked by determination of
the percentage of rod-shaped cells and averaged 90-95% 
under all incubation conditions. 
2.2. Measurement of  DAG mass 
Cardiomyocytes were incubated at 37°C in Hepes buffer 
for the indicated times. The lipid fraction was then ex- 
tracted by a modification of the method of Bligh and Dyer 
[24]. Assay of DAG mass was performed using the Amer- 
sham DAG assay reagent system, which is based on the 
method of Preiss et al. [25]. The DAG in the lipid extract 
was converted quantitatively to [32 P]phosphatidic acid by 
DAG kinase in the presence of [ 3,-32 P]ATP. [ 32 P]Phospha- 
tidic acid was then separated by polar extraction using 
silica Amprep minicolumns and the associated radioactiv- 
ity was determined. DAG levels were calculated from 
standard curves generated in parallel. Significance of re- 
ported differences was evaluated using the null hypothesis 
and t statistics for paired data. 
2.3. 3-O-Methylglucose transport 
Transport experiments were performed at 37°C in Hepes 
buffer containing MgCI 2 (1 mM) and CaC12 (1 mM). The 
reaction was started by pipetting a50/zl aliquot of the cell 
suspension to 50 /~1 of Hepes buffer containing 3-0- 
[14C]methyl-D-glucose (final concentration 100 /xM). Car- 
rier-mediated glucose transport was then determined using 
a 10 s assay period and L-[X4C]glucose in order to correct 
for simple diffusion as described in earlier reports from 
this laboratory [19-21]. 
2.4. Protein kinase C assay 
Cardiomyocytes (5 • 105 cells/0.5 ml) were exposed to 
PMA or insulin for the indicated times. Cells were then 
homogenized in a buffer containing 20 mM Hepes, 5 mM 
EGTA, 0.25 mM sucrose, 5 mM DTr, 1 g/1 BSA and 50 
/xg/ml leupeptin by sonication (five times for 10 s) fol- 
lowed by 9 × 4 strokes in a glass potter homogenizer. The 
whole homogenate was centrifuged for 45 min at 100 000 
× g and the supernatant was considered as the cytosolic 
fraction. The pellet was solubilized in homogenizing buffer 
containing 0.4% Triton X-100 and centrifuged at 10 000 × 
g for 10 min. Both fractions were then applied to DEAE- 
cellulose columns, which were washed with 2.5 ml of a 
buffer containing 20 mM Tris-HC1 (pH 7.4), 2 mM EDTA, 
5 mM EGTA and 2 mM PMSF. PKC was eluted with the 
same buffer containing 100 mM NaC1. PKC activity was 
then determined by measuring the Ca 2+ and phospho- 
lipid-dependent transfer of 32p from [32p]ATP to histone 
III-S. 100 /zl of the eluate was added to 150 brl of a 
solution containing 20 mM Tris-HCl (pH 7.5), 10 mM 
magnesium acetate, 25 tzg histone III-S either in the 
absence or presence of 0.75 mM CaC12, 12 /zg of 
phosphatidylserine and 1.6/.~g of 1,2-diolein. The reaction 
was started by addition of 50 /zM ATP containing 5 /zCi 
of [32p]ATP per assay and conducted for 30 min at room 
temperature. Histone was then precipitated by addition of 
ice-cold 25% trichloroacetic acid and separated by filtra- 
tion on 0.45 /~m nitrocellulose filters. Filters were then 
counted by liquid scintillation. All data were corrected for 
phospholipid-independent kinase activity. Translocation of 
PKC was determined by measuring the ratio of membrane 
associated activity/total ctivity (total activity is cytosolic 
activity plus particulate activity). 
2.5. Chemicals 
[~_32 P]ATP (6000 Ci/mmol) was purchased from New 
England Nuclear (Germany). 3-0-[14 C]Methyl-D-glucose 
(57 Ci/mmol), L-[1-14C]glucose (58 Ci/mmol), the DAG 
assay reagent system, and Amprep minicolunms were from 
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Amersham (Germany). PMA, 4-a-phorbol 12,13-dide- 
canoate (PDD), phosphatidylserine, 1,2-diolein, histone 
III-S and phospholipase C fi'om Clostridium perfringens 
were obtained from Sigma (Germany). Staurosporine was 
from Calbiochem (Germany). All other chemicals were of 
the highest grade commercially available. 
3. Results 
Intracellular DAG is known to act as the endogenous 
activator of PKC. Furthermore, it has been suggested that 
DAG may mediate insulin action directly through an in- 
crease in the recruitment and/or intrinsic activity of glu- 
cose transporters [7]. As shown in Table 1, insulin was 
unable to increase the intracellular DAG mass in ventricu- 
lar cardiomyocytes after 30 min of incubation, whereas 
under these conditions a large stimulation of glucose trans- 
port could be observed. Treatment of cells with PLC-Cp 
was found to increase the DAG level by a factor of two. 
However, despite this increase in DAG mass, PLC-Cp did 
not modify the initial rates of 3-O-methylglucose transport 
(Table 1), in contrast o BC3H-1 myocytes, where both 
PLC-Cp and exogenously added DAG produced a 2-3-fold 
increase of glucose transport [7]. In order to rule out a 
transient increase of DAG, the kinetics of insulin action on 
DAG mass in cardiomyocytes were investigated. Using a 
maximally active dose of the hormone, a slight (maximum 
19% at 20 min) but insignificant increase was observed at 
all time points studied (Fig. 1). Similar results were ob- 
tained at lower insulin concentrations. 
It may be argued that the insulin-dependent DAG pool 
in cardiomyocytes represents only a small part of total 
DAG mass or that PKC activation by insulin is mediated 
by factors other than DAG [8]. We have therefore deter- 
mined the time-dependent effect of insulin on the mem- 
brane association of PKC and compared it to the action of 
the phorbolester PMA, which was found to induce a rapid 
translocation of PKC in adult cardiomyocytes [26] includ- 
ing all isoforms present in these cells (or, /~, E), as shown 
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Fig. 1. Time-related effects of insulin on 1,2-diacylglycerol content of 
ventricular cardiomyocytes. Cells were incubated at 37°C for the indi- 
cated times in the absence or presence of insulin (3.5-10 -7 M). The lipid 
fraction was extracted and DAG mass levels were assayed as described in 
Section 2. Data are mean values+S.E. (n = 3) expressed as percent of 
untreated controls. P values were determined by paired t-test. 
in a very recent report by Puc6at et al. [27]. The membrane 
association of PKC expressed as the ratio of membrane 
activity/total activity is presented in Fig. 2. The data 
clearly show that insulin is unable to induce a translocation 
of PKC both after a 5 or a 20 rain incubation time with the 
hormone, whereas the phorbol ester increased membrane- 
associated PKC twofold. It should be noted that the total 
PKC activity (53.8 pmol/min/106 cells) even slightly 
PKC distribution (M/C+M) 
1'0 I 
Table 1 
Effect of insulin and phospholipase C on 1,2-diacylglycerol mass and 
glucose transport in ventricular cardiomyocytes 
Incubation DAG content 3-O-Methylglucose 
condition (nmol/1.5 •106 cell,;) transport 
(pmol/106 cells × 10 s) 
Basal 17.5 + 2.1 (5) 357 + 34 (4) 
Insulin 14.5 4:-1.4 a (5) 945 + 51 (4) 
PLC-Cp 35.3 + 3.9 (3) 409 + 77 a (4) 
Cardiomyocytes were incubated at 37°C for 30 min in the absence or 
presence of either insulin (3.5.10 -'7 M) or PLC-Cp (0.2 U/ml). DAG 
mass levels and 3-O-methylglucose transport were then determined as 
described in Section 2. Data are mean values + S.E. for the number of 
experiments indicated in parentheses.. 
a Not significantly different from basal (P > 0.05). 
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Fig. 2. Effect of insulin and PMA on membrane association of PKC. 
Cardiomyocytes were incubated in the absence or presence of either 
insulin (3.5.10 -7 M) or PMA (1 /~M, 30 min). Analysis of membrane 
and cytosolic PKC activity was performed as described in Section 2. PKC 
distribution is expressed as the ratio of membrane activity (M)/cytosolic 
activity (C) + M. Data are mean values + S.E. (n = 3-4). 
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Table 2 
Effect of PKC inhibitors on basal and insulin-stimulated glucose transport 
in cardiomyocytes 
Addition 3-O-Methylglucose transport 
(pmol/106 ceils x 10 s) 
Basal Insulin Increment 
Control 485 + 5 1350 -[- 83 865 
Tamoxifen 374 + 24 a 1105 + 79 731 
Control 394 _+ 37 1126 -1- 35 732 
Staurosporine 162 + 35 a 804 _+ 31 642 
Cells were incubated for 30 min in the absence (control) or presence of 
tamoxifen (100/xM) or staurosporine (1 /zM), then stimulated for 30 min 
with insulin (3.5.10 -7 M) prior to assay of initial 3-O-methylglucose 
transport ates. Data are mean values + S.E. of 3-5 separate xperiments. 
a Significantly different from control with P < 0.05. 
in Fig. 3, PMA produced no significant increase of basal 
glucose transport when compared to the inactive phorbol 
analogue PDD. Furthermore, the maximal response was 
also not affected by PKC activation. However, PMA was 
found to produce a rightward shift of the dose-response 
curve resulting in significantly lower insulin-stimulated 
transport rates at 3 • 10 1] and 10-10 M (Fig. 3), suggest- 
ing a reduced insulin sensitivity of PMA-treated cardiac 
cells. Under these conditions a slight (21%) but significant 
(P  = 0.0065) reduction of insulin binding could also be 
detected. 
4. Discussion 
(30%) decreased in insulin-treated cells, whereas it re- 
mained unaffected after PMA treatment. 
The data reported so far strongly suggest hat insulin 
action on cardiac glucose transport is not mediated by 
PKC. Additional evidence for this conclusion was obtained 
from experiments using the protein kinase C inhibitors 
tamoxifen and staurosporine. Both drugs were found to 
reduce the basal glucose transport rates by 20-60%. How- 
ever, the incremental increase in glucose transport due to 
stimulation with insulin was not significantly affected by 
the PKC inhibitors (Table 2). 
Despite apparently not being involved in the transduc- 
tion of the insulin signal to the cardiac glucose transporter, 
PKC may interfere with insulin signalling potentially lead- 
ing to a loss of insulin sensitivity or responsiveness, as
shown in other cellular systems [12,13,28]. We have there- 
fore evaluated the effect of PKC activation by PMA on 
basal and insulin-stimulated glucose transport. As shown 
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Fig. 3. Dose-response r lationship for insulin stimulated transport of 
3-O-methylglucose. Myocytes were treated for 30 min with 1 p~M of 
either PDD or PMA. Incubation was then continued for 60 min in the 
presence of increasing concentrations of insulin (3.5.10- ]1 to 3.5.10- 7 
tool/l). Hexose uptake was determined as outlined in Fig. 1. The data 
shown are mean values+S.E. (n = 3-6). P values were determined for 
PDD versus PMA at corresponding insulin concentrations u ing paired 
t-test. 
The putative involvement of PKC in the process of 
signal transduction from the insulin receptor to the glucose 
transporter has remained a controversial nd unresolved 
issue. The present investigation has examined this relation- 
ship in ventricular cardiomyocytes, since (a) these primary 
muscle cells express a high level of the insulin responsive 
glucose transporter Glut4 [21], and (b) PKC is of addi- 
tional importance for the regulation of contractility [22] 
and gene expression [23] in these cells. Our data suggest 
that the acute action of insulin on cardiac glucose uptake is 
independent of PKC activation. Three lines of evidence 
support his conclusion. First, insulin was unable to modify 
the DAG content of cardiomyocytes, second, no activa- 
tion/translocation f PKC in response to the hormone 
could be detected, and third, inhibitors of PKC did not 
affect the insulin-stimulated glucose uptake. 
A major finding of the present report consists in the 
observation that insulin was unable to increase the DAG 
mass in cardiomyocytes. This contrasts with the BC3H-1 
myocytes, which show a rapid (2 min) and sustained 
2-3-fold increase of DAG-content in response to insulin 
resulting from multiple sources [6,7,29]. However, this 
large response may be specific for the BC3H-1 cell, since 
Farese's group reported a relatively small DAG increase 
(20-30%) in skeletal muscle after in vitro [30] and in vivo 
[8] insulin treatment. Furthermore, Turinsky et al. [15] 
observed an unaltered DAG level in rat skeletal muscle 
after in vivo administration of insulin and Merrall et al. 
[14] reported the inability of insulin to modify the DAG 
level of 3T3-L1 fibroblasts. Interestingly, phospholipase C 
had essentially no effect on glucose uptake by cardiomy- 
ocytes despite inducing a twofold increase in DAG mass in 
these cells. On the other hand, PLC-Cp was found to 
mimick insulin action in BC3H-1 myocytes [7] and 
adipocytes [31]. However, it has to be considered that 
PLC-Cp is also able to increase the cytosolic Ca 2 + concen- 
tration which may then lead to an increased glucose trans- 
port, as shown by Henriksen et al. [16] in skeletal muscle. 
We therefore conclude that lipolytically produced DAG 
does not act as a mediator of insulin action on cardiac 
glucose transport. 
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As outlined by Farese's group [8], a small but metaboli- 
cally active, insulin-dependent DAG pool or factors other 
than DAG could participate in the PKC translocation 
response. However, we have ruled out this possibility for 
the cardiomyocytes by (I) showing that insulin is unable to 
promote the membrane association of PKC, and (II) 
demonstrating an unaltered insulin action in the presence 
of PKC inhibitors. In agreement with our findings, no 
effect of insulin on PKC translocation or activation was 
observed in L6 skeletal muscle cells [32] and 3T3-L1 
fibroblasts [14], it was however assayed in rat adipocytes 
[9]. In rat skeletal muscle an insulin-induced translocation 
of PKC was reported for soleus and gastrocnemius muscle 
[8], but could not be detected in epitrochlearis muscles 
[16]. A possible key to explaining these apparent contro- 
versial findings obtained by different laboratories may be 
related to a different pattern of PKC isoforms in different 
tissues or cell lines, since in,;ulin and phorbol esters were 
found to have overlapping and distinctly different effects 
on the redistribution of PKC isoforms [33]. Thus, insulin 
but not PMA stimulated the translocation of PKC-fl in 
adipocytes, whereas PMA was much more effective on the 
redistribution of PKC-a [33]. Very recently, Puc6at et al. 
showed that PKC-fl is not expressed in adult rat cardiomy- 
ocytes [27]. It may be speculated that the lack of insulin 
action on PKC translocation shown in the present study is 
related to the specific pattern of PKC isoform expression 
in the heart. This hypothesis needs further investigation. 
Nevertheless, the data clearly indicate that PKC transloca- 
tion/activation is not an essential requirement for insulin 
action on muscle tissue. 
Additional evidence to exclude the involvement of PKC 
signalling to cardiomyocyte glucose transport was obtained 
from the inability of PMA to affect hexose transport in 
these cells. Consistently, only minimal effects of PMA on 
glucose transport in different rat skeletal muscle prepara- 
tions have been reported [16,18]. In contrast o our find- 
ings, van de Werve et al. [34] observed a 3-fold increase in 
3-O-methylglucose effiux by PMA in isolated perfused 
hearts, suggesting stimulation of glucose transport by PKC 
activation. However, the mechanisms of PMA-stimulated 
glucose transport remain controversial. Thus, Gibbs et al. 
[35] recently showed that insulin and PMA act via differ- 
ent mechanisms, whereas earlier work suggested that PMA 
induces a translocation of ghlcose transporters to an extent 
comparable with that induced by insulin [36]. Furthermore, 
PMA acts on both Glutl and Glut4 [35] and this may at 
least partly explain the different results obtained with 
cardiomyocytes and perfused heart tissue [34]. 
Despite being unable to affect basal glucose transport, 
PMA was found to produce a rightward shift of the 
dose-response curve for insulin-stimulated glucose trans- 
port resulting in a reduced sensitivity at physiological 
concentrations of the hormone. Thus, PKC activation is 
able to modify insulin signalling in the cardiac cell. This 
finding agrees well with the data obtained in perfused 
heart tissue [34] and earlier observations on isolated 
adipocytes [12]. In these cells the insulin resistance in- 
duced by PMA was shown to result from a large inhibition 
of the insulin receptor kinase, most probably due to serine 
phosphorylation of the insulin receptor [12]. The precise 
location of PMA-induced desensitization in cardiomy- 
ocytes remains to be elucidated. Reduced receptor binding, 
as reported here, may only marginally contribute to this 
process and additional alterations at the receptor [12] and 
the postreceptor level [28] have to be considered. 
Taken together, the present study shows that the 
DAG/PKC signalling system does not mediate the stimu- 
latory action of insulin on cardiac glucose transport. In- 
stead, PKC activation induces insulin resistance by modi- 
fying the sensitivity of the cardiac cell. 
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